Appili Therapeutics Inc. and its partner Vitalex Biosciences LLC have announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded up to $40 million in funding to support the development of VXV-01, a vaccine aimed at protecting against invasive fungal infections.